CEACAM-5 靶点蛋白|抗体药物|临床药物信息

CEACAM-5信息

英文名称：Carcinoembryonic antigen related cell adhesion molecule 5
中文名称：癌胚抗原相关细胞粘附分子5
靶点别称：CEACAM5，Meconium antigen 100，CEA，Carcinoembryonic Antigen Related Cell Adhesion Molecule 5，Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5，Carcinoembryonic Antigen，CD66e Antigen，CD66e，CEA Cell Adhesion Molecule 5

上市药物数量：1
临床药物数量：12
最高研发阶段：批准上市

CEACAM-5产品列表

筛选结果

产品库

物种

标签

属性

Protein (7)

标记

货号	物种	产品描述
CE5-H5226	Human	Human CEACAM-5 / CD66e Protein, His Tag (MALS verified)
CE5-H82E0	Human	Biotinylated Human CEACAM-5 / CD66e Protein, His,Avitag™
CE5-HF254	Human	FITC-Labeled Human CEACAM-5 / CD66e Protein, His Tag (MALS verified)
CE5-C52H3	Cynomolgus	Cynomolgus CEACAM-5 Protein, His Tag
CE5-M5253	Mouse	Mouse CEACAM-5 Protein, Fc Tag
CE5-H5253	Human	Human CEACAM-5 Protein, Fc Tag
CE5-M52H3	Mouse	Mouse CEACAM-5 Protein, His Tag

CEACAM-5 Molecule Synonym Name

CEACAM-5,CD66e,CEA,Meconium antigen 100

CEACAM-5 分子背景

Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is also Carcinoembryonic antigen (CEA), Meconium antigen 100, CD antigen CD66e, CEACAM5 belongs to the immunoglobulin superfamily and CEA family. CEACAM5 contains seven Ig-like (immunoglobulin-like) domains. CEACAM5 is homodimer protein which binding of E.coli Dr adhesins leads to dissociation of the homodimer. CEACAM5 is cell surface glycoprotein that plays a role in cell adhesion and in intracellular signaling. CEACAM5 is receptor for E.coli Dr adhesins.

CEACAM-5 参考文献

CEACAM-5上市药物信息

英文名称	中文名称	研发代码	研发阶段	公司	最早商品名	最早批准国家	最早适应症	最早批准公司	最早批准日期	适应症	临床试验
Arcitumomab		IMMU-4-[99mTc]; [99mTc]-IMMU-4	批准上市	Immunomedics	CEA-Scan, Immu RAID-CEA	United States	结直肠癌	Immunomedics Inc	1996-06-28	结直肠癌

CEACAM-5临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
MFE-23-CD3z T cell therapy (Cancer Research Technology)		临床一期	Cancer Research Technology	肿瘤
Recombinant Saccharomyces cerevisiae-CEA	GI-6207	临床二期	Globeimmune	头颈部鳞状细胞癌, 三阴性乳腺肿瘤, 胰腺癌, 移行细胞癌, 甲状腺髓样癌, 结直肠癌, 鳞状细胞癌, 甲状腺瘤, 非小细胞肺癌, 黑色素瘤, 肝细胞癌	详情
TF 2-targeted cancer therapy	TF-2	临床二期	Immunomedics, Ibc Pharmaceuticals	小细胞肺癌, 皮肤肥大细胞增生症, 乳腺癌, 结直肠癌, 甲��腺瘤, 非小细胞肺癌	详情
Anti-CEA CAR T cell therapy (Shanghai GeneChem)	MG7-CART	临床二期	西京医院第四军医大学, 上海吉凯基因医学科技股份有限公司	肝癌, 结直肠癌
Cergutuzumab amunaleukin	RG-7813; RO-6895882	临床一期	罗氏	肿瘤	详情
Labetuzumab govitecan	IMMU-130; hMN-14-SN38	临床二期	Immunomedics, Ibc Pharmaceuticals	直肠癌, 结肠癌, 乳腺癌, 结直肠癌	详情
NEO-201	NEO-201	临床一期	Precision Biologics, 美国国立癌症研究所	肺腺癌, 胰腺癌, 乳腺癌, 结直肠癌, 鳞状细胞癌	详情
SGM-101	SGM-101	临床三期	Surgimab	胃癌, 直肠癌, 结肠癌, 胰腺癌, 乳腺癌, 结直肠癌	详情
Cibisatamab	CEA-TCB; RG-7802; RO-6958688; CEA-CD3 TCB	临床二期	罗氏	肿瘤, 结直肠癌, 非小细胞肺癌	详情
Carcinoembryonic antigen autologous dendritic cell vaccine (Duke University)		临床二期	杜克大学	肿瘤	详情
Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute)	CV-301; CVAC-301	临床三期	Therion Biologics	卵巢癌, 胰腺癌, 膀胱癌, 前列腺癌, 乳腺癌, 结直肠癌, 非小细胞肺癌	详情
SAR-408701	SAR-408701	临床三期	Immunogen	胰腺癌, 乳腺癌, 非小细胞肺癌	详情

会议日历

会议一览

CEACAM-5 重组蛋白